References
  1. Proal AD, VanElzakker MB. Long Covid or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Frontiers in Microbiology. 2021;12. doi:10.3389/fmicb.2021.698169
  2. Yong SJ. Long Covid or post-covid-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infectious Diseases. 2021;53(10):737–54. doi:10.1080/23744235.2021.1924397
  3. Argento E, Christie D, Mackay L, Callon C, Walsh Z. Psychedelic-assisted psychotherapy after COVID-19: The therapeutic uses of Psilocybin and MDMA for pandemic-related mental health problems. Frontiers in Psychiatry. 2021;12. doi:10.3389/fpsyt.2021.716593
  4. Kurtz JS, Patel NA, Gendreau JL, Yang C, Brown N, Bui N, et al. The use of psychedelics in the treatment of medical conditions: An analysis of currently registered psychedelics studies in the American Drug Trial Registry. Cureus. 2022; doi:10.7759/cureus.29167
  5. Herrera JE, Niehaus WN, Whiteson J, Azola A, Baratta JM, Fleming TK, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of sars‐cov‐2 infection patients. PM&R. 2021;13(9):1027–43. doi:10.1002/pmrj.12684
  6. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long covid: Major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21(3):133–46. doi:10.1038/s41579-022-00846-2
  7. Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH, et al. Default mode network modulation by psychedelics: A systematic review. International Journal of Neuropsychopharmacology. 2022;26(3):155–88. doi:10.1093/ijnp/pyac074
  8. Kapoor A, Mahajan G, Kapur A. State of brain networks in long covid: Post mild to moderate acute COVID-19 disease. SSRN Electronic Journal. 2022;1–26. doi:10.2139/ssrn.4309672
  9. Martin DA, Nichols CD. The effects of hallucinogens on gene expression. Behavioral Neurobiology of Psychedelic Drugs. 2017;137–58. doi:10.1007/7854_2017_479